Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration

DSpace/Manakin Repository

Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration

Citable link to this page

 

 
Title: Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration
Author: Asztalos, Bela F.; Schaefer, Ernst J.; Sell, David R.; Strauch, Christopher M.; Monnier, Vincent M.; Sun, Jennifer Katherine; Keenan, Hillary; Cavallerano, Jerry D.; Doria, Alessandro; Aiello, Lloyd Paul; King, George Liang

Note: Order does not necessarily reflect citation order of authors.

Citation: Sun, Jennifer K., Hillary A. Keenan, Jerry D. Cavallerano, Bela F. Asztalos, Ernst J. Schaefer, David R. Sell, Christopher M. Strauch, et al. 2011. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration. Diabetes Care 34(4): 968-974.
Full Text & Related Files:
Abstract: Objective: To assess complication prevalence and identify protective factors in patients with diabetes duration of \(\geq\)50 years. Characterization of a complication-free subgroup in this cohort would suggest that some individuals are protected from diabetes complications and allow identification of endogenous protective factors. Research Design and Methods: Cross-sectional, observational study of 351 U.S. residents who have survived with type 1 diabetes for \(\geq\)50 years (Medalists). Retinopathy, nephropathy, neuropathy, and cardiovascular disease were assessed in relation to HbA\(_{1c}\), lipids, and advanced glycation end products (AGEs). Retrospective chart review provided longitudinal ophthalmic data for a subgroup. Results: A high proportion of Medalists remain free from proliferative diabetic retinopathy (PDR) (42.6%), nephropathy (86.9%), neuropathy (39.4%), or cardiovascular disease (51.5%). Current and longitudinal (the past 15 years) glycemic control were unrelated to complications. Subjects with high plasma carboxyethyl-lysine and pentosidine were 7.2-fold more likely to have any complication. Of Medalists without PDR, 96% with no retinopathy progression over the first 17 years of follow-up did not experience retinopathy worsening thereafter. Conclusions: The Medalist population is likely enriched for protective factors against complications. These factors might prove useful to the general population with diabetes if they can be used to induce protection against long-term complications. Specific AGE combinations were strongly associated with complications, indicating a link between AGE formation or processing with development of diabetic vasculopathy.
Published Version: doi:10.2337/dc10-1675
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064059/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10336903
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters